Cristina Dallabona1, Daria Diodato1, Sietske H Kevelam1, Tobias B Haack1, Lee-Jun Wong1, Gajja S Salomons1, Enrico Baruffini1, Laura Melchionda1, Caterina Mariotti1, Tim M Strom1, Thomas Meitinger1, Holger Prokisch1, Kim Chapman1, Alison Colley1, Helena Rocha1, Katrin Ounap1, Raphael Schiffmann1, Ettore Salsano1, Mario Savoiardo1, Eline M Hamilton1, Truus E M Abbink1, Nicole I Wolf1, Ileana Ferrero1, Costanza Lamperti1, Massimo Zeviani1, Adeline Vanderver1, Daniele Ghezzi2, Marjo S van der Knaap2. 1. From the Department of Life Sciences (C.D., E.B., I.F.), University of Parma; Unit of Molecular Neurogenetics (D.D., L.M., C.L., D.G.), SOSD Genetics of Neurodegenerative and Metabolic Diseases (C.M.), and Departments of Clinical Neurosciences (E.S.) and Neuroradiology (M.S.), Fondazione Istituto Neurologico Carlo Besta, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy; Department of Child Neurology (S.H.K., E.M.H., T.E.M.A., N.I.W., M.S.v.d.K.), Department of Clinical Chemistry, Metabolic Unit (G.S.S.), Neuroscience Campus Amsterdam, and Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (M.S.v.d.K.), VU University Medical Center, Amsterdam, the Netherlands; Institute of Human Genetics (T.B.H., T.M.S., T.M., H.P.), Technical University, Munich; Institute of Human Genetics (T.B.H., T.M.S., T.M., H.P.), Helmholtz Zentrum Munich, Neuherberg, Germany; Department of Molecular and Human Genetics (L.-J.W.), Baylor College of Medicine, Houston, TX; Department of Genetics (K.C.), and Center for Genetic Medicine Research, Department of Neurology (A.V.), Children's National Medical Center, Washington, DC; Department of Clinical Genetics (A.C.), Liverpool Hospital, Sydney, Australia; Neurology Department (H.R.), Centro Hospitalar São João, and Department of Clinical Neuroscience and Mental Health, Faculty of Medicine, University of Porto, Portugal; Medical Genetics Center (K.Ő.), United Laboratories, Tartu University Clinics, Estonia; Institute of Metabolic Disease (R.S.), Baylor Research Institute, Dallas, TX; and Mitochondrial Biology Unit-MRC (M.Z.), Cambridge, UK. 2. From the Department of Life Sciences (C.D., E.B., I.F.), University of Parma; Unit of Molecular Neurogenetics (D.D., L.M., C.L., D.G.), SOSD Genetics of Neurodegenerative and Metabolic Diseases (C.M.), and Departments of Clinical Neurosciences (E.S.) and Neuroradiology (M.S.), Fondazione Istituto Neurologico Carlo Besta, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy; Department of Child Neurology (S.H.K., E.M.H., T.E.M.A., N.I.W., M.S.v.d.K.), Department of Clinical Chemistry, Metabolic Unit (G.S.S.), Neuroscience Campus Amsterdam, and Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (M.S.v.d.K.), VU University Medical Center, Amsterdam, the Netherlands; Institute of Human Genetics (T.B.H., T.M.S., T.M., H.P.), Technical University, Munich; Institute of Human Genetics (T.B.H., T.M.S., T.M., H.P.), Helmholtz Zentrum Munich, Neuherberg, Germany; Department of Molecular and Human Genetics (L.-J.W.), Baylor College of Medicine, Houston, TX; Department of Genetics (K.C.), and Center for Genetic Medicine Research, Department of Neurology (A.V.), Children's National Medical Center, Washington, DC; Department of Clinical Genetics (A.C.), Liverpool Hospital, Sydney, Australia; Neurology Department (H.R.), Centro Hospitalar São João, and Department of Clinical Neuroscience and Mental Health, Faculty of Medicine, University of Porto, Portugal; Medical Genetics Center (K.Ő.), United Laboratories, Tartu University Clinics, Estonia; Institute of Metabolic Disease (R.S.), Baylor Research Institute, Dallas, TX; and Mitochondrial Biology Unit-MRC (M.Z.), Cambridge, UK. ms.vanderknaap@vumc.nl dghezzi@istituto-besta.it.
Abstract
OBJECTIVES: The study was focused on leukoencephalopathies of unknown cause in order to define a novel, homogeneous phenotype suggestive of a common genetic defect, based on clinical and MRI findings, and to identify the causal genetic defect shared by patients with this phenotype. METHODS: Independent next-generation exome-sequencing studies were performed in 2 unrelated patients with a leukoencephalopathy. MRI findings in these patients were compared with available MRIs in a database of unclassified leukoencephalopathies; 11 patients with similar MRI abnormalities were selected. Clinical and MRI findings were investigated. RESULTS: Next-generation sequencing revealed compound heterozygous mutations in AARS2 encoding mitochondrial alanyl-tRNA synthetase in both patients. Functional studies in yeast confirmed the pathogenicity of the mutations in one patient. Sanger sequencing revealed AARS2 mutations in 4 of the 11 selected patients. The 6 patients with AARS2 mutations had childhood- to adulthood-onset signs of neurologic deterioration consisting of ataxia, spasticity, and cognitive decline with features of frontal lobe dysfunction. MRIs showed a leukoencephalopathy with striking involvement of left-right connections, descending tracts, and cerebellar atrophy. All female patients had ovarian failure. None of the patients had signs of a cardiomyopathy. CONCLUSIONS: Mutations in AARS2 have been found in a severe form of infantile cardiomyopathy in 2 families. We present 6 patients with a new phenotype caused by AARS2 mutations, characterized by leukoencephalopathy and, in female patients, ovarian failure, indicating that the phenotypic spectrum associated with AARS2 variants is much wider than previously reported.
OBJECTIVES: The study was focused on leukoencephalopathies of unknown cause in order to define a novel, homogeneous phenotype suggestive of a common genetic defect, based on clinical and MRI findings, and to identify the causal genetic defect shared by patients with this phenotype. METHODS: Independent next-generation exome-sequencing studies were performed in 2 unrelated patients with a leukoencephalopathy. MRI findings in these patients were compared with available MRIs in a database of unclassified leukoencephalopathies; 11 patients with similar MRI abnormalities were selected. Clinical and MRI findings were investigated. RESULTS: Next-generation sequencing revealed compound heterozygous mutations in AARS2 encoding mitochondrial alanyl-tRNA synthetase in both patients. Functional studies in yeast confirmed the pathogenicity of the mutations in one patient. Sanger sequencing revealed AARS2 mutations in 4 of the 11 selected patients. The 6 patients with AARS2 mutations had childhood- to adulthood-onset signs of neurologic deterioration consisting of ataxia, spasticity, and cognitive decline with features of frontal lobe dysfunction. MRIs showed a leukoencephalopathy with striking involvement of left-right connections, descending tracts, and cerebellar atrophy. All female patients had ovarian failure. None of the patients had signs of a cardiomyopathy. CONCLUSIONS: Mutations in AARS2 have been found in a severe form of infantile cardiomyopathy in 2 families. We present 6 patients with a new phenotype caused by AARS2 mutations, characterized by leukoencephalopathy and, in female patients, ovarian failure, indicating that the phenotypic spectrum associated with AARS2 variants is much wider than previously reported.
Authors: Petri Luoma; Atle Melberg; Juha O Rinne; Jyrki A Kaukonen; Nina N Nupponen; Richard M Chalmers; Anders Oldfors; Ilkka Rautakorpi; Leena Peltonen; Kari Majamaa; Hannu Somer; Anu Suomalainen Journal: Lancet Date: 2004 Sep 4-10 Impact factor: 79.321
Authors: Marianne E Steenweg; Petra J W Pouwels; Nicole I Wolf; Wessel N van Wieringen; Frederik Barkhof; Marjo S van der Knaap Journal: Brain Date: 2011-10-17 Impact factor: 13.501
Authors: Daniele Ghezzi; Enrico Baruffini; Tobias B Haack; Federica Invernizzi; Laura Melchionda; Cristina Dallabona; Tim M Strom; Rossella Parini; Alberto B Burlina; Thomas Meitinger; Holger Prokisch; Ileana Ferrero; Massimo Zeviani Journal: Am J Hum Genet Date: 2012-05-17 Impact factor: 11.025
Authors: Gert C Scheper; Thom van der Klok; Rob J van Andel; Carola G M van Berkel; Marie Sissler; Joél Smet; Tatjana I Muravina; Sergey V Serkov; Graziella Uziel; Marianna Bugiani; Raphael Schiffmann; Ingeborg Krägeloh-Mann; Jan A M Smeitink; Catherine Florentz; Rudy Van Coster; Jan C Pronk; Marjo S van der Knaap Journal: Nat Genet Date: 2007-03-25 Impact factor: 38.330
Authors: Alexandra Götz; Henna Tyynismaa; Liliya Euro; Pekka Ellonen; Tuulia Hyötyläinen; Tiina Ojala; Riikka H Hämäläinen; Johanna Tommiska; Taneli Raivio; Matej Oresic; Riitta Karikoski; Outi Tammela; Kalle O J Simola; Anders Paetau; Tiina Tyni; Anu Suomalainen Journal: Am J Hum Genet Date: 2011-05-05 Impact factor: 11.025
Authors: Johannes A Mayr; Tobias B Haack; Elisabeth Graf; Franz A Zimmermann; Thomas Wieland; Birgit Haberberger; Andrea Superti-Furga; Janbernd Kirschner; Beat Steinmann; Matthias R Baumgartner; Isabella Moroni; Eleonora Lamantea; Massimo Zeviani; Richard J Rodenburg; Jan Smeitink; Tim M Strom; Thomas Meitinger; Wolfgang Sperl; Holger Prokisch Journal: Am J Hum Genet Date: 2012-01-26 Impact factor: 11.025
Authors: William W Motley; Laurie B Griffin; Inès Mademan; Jonathan Baets; Els De Vriendt; Peter De Jonghe; Anthony Antonellis; Albena Jordanova; Steven S Scherer Journal: Neurology Date: 2015-04-22 Impact factor: 9.910
Authors: Cas Simons; Laurie B Griffin; Guy Helman; Gretchen Golas; Amy Pizzino; Miriam Bloom; Jennifer L P Murphy; Joanna Crawford; Sarah H Evans; Scott Topper; Matthew T Whitehead; John M Schreiber; Kimberly A Chapman; Cyndi Tifft; Katrina B Lu; Howard Gamper; Megumi Shigematsu; Ryan J Taft; Anthony Antonellis; Ya-Ming Hou; Adeline Vanderver Journal: Am J Hum Genet Date: 2015-03-26 Impact factor: 11.025
Authors: Jason H Peragallo; Stephanie Keller; Marjo S van der Knaap; Bruno P Soares; Suma P Shankar Journal: Ophthalmic Genet Date: 2017-08-18 Impact factor: 1.803